Goederenrecht

Coherent privaatrech

De bevoor(oor)deelde arbiter: een onderzoek naar de verplichting tot arbitrale onafhankelijkheid en onpartijdigheid

This thesis focuses on the duty of independence and impartiality for arbitrators. The starting point is unambiguous: an arbitrator should be independent and impartial. Less unambiguous is the answer to the question of what this duty of arbitral independence and impartiality entails. This thesis aimed to shed light on this (general) research question.The objective of this doctoral research was twofold. On the one hand, the objective was to gain insight into the way in which the duty of arbitral independence and impartiality is interpreted judicially. To this end, it was examined how the duty is interpreted in arbitration legislation, institutional rules, and (arbitral) court rulings. On the other hand, the objective was to shed light on a number of (open) questions related to the scope of the duty. In this respect, it was examined, among other things, who exactly is subject to the duty, how the duty emerges in arbitration legislation and institutional rules, what the duty aims to achieve, the question from when and to when arbitrators must be independent and impartial, and whether the parties can waive the right to an independent and impartial arbitrator. Swaantje Mondt Fonds (LUF)Coherent privaatrech

Arbitrage en de 'Mona Lisa van Oostenrijk'

Coherent privaatrech

Goederenrecht

Coherent privaatrech

Contractenrecht

Coherent privaatrech

Haemophilia care in Europe:a survey of 19 countries

In 2009, a questionnaire was circulated to 19 national haemophilia patient organizations in Europe affiliated to the European Haemophilia Consortium (EHC) and the World Federation of Hemophilia (WFH) to seek information about the organization of haemophilia care and treatment available at a national level. The responses received highlighted differences in the level of care despite the recent promulgation of consensus guidelines designed to standardize the care of haemophilia throughout the continent of Europe. There was a wide range in factor VIII consumption with usage ranging from 0.38 IU per capita in Romania to 8.7 IU per capita in Sweden (median: 3.6 IU per capita). Despite the specific inclusion of coagulation factor concentrate in the WHO list of essential medications, cryoprecipitate is still used in some eastern European countrie

Toepassing van Europees recht door arbiters en bindend adviseurs in Nederland: Quis custodiet ipsos custodes?

Coherent privaatrech

Arbitrage, afstand van recht en artikel 6 EVRM

Coherent privaatrech